
LIXTE Biotechnology Advances Tumor Immunogenicity Research with Lead Compound LB-100
LIXTE Biotechnology is advancing its lead compound LB-100, which targets tumor immunogenicity to potentially enhance responsiveness to existing cancer immunotherapies, addressing the critical challenge of immunologically 'cold' tumors that resist current treatments.
Read full story

























